LANDMARC Study: a Study With Focus on Aorta Ascendens
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Dec 16, 2022
Trial Information
Current as of February 05, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years and older
- • Able to understand the trial and provide informed consent
- • Patients who have participated in the FIBAA-bank
- Exclusion Criteria:
- • Patients with abnormal congenital cardiothoracic anatomy, with exception of presence of a bicuspid aortic valve
- • Patients with history of chemotherapy, or radiotherapy within thoracic region
- • Patients with an age \>80 years
- • Patients with a weight \>120 kg
- • Patients with a contra-indication for MRI according to the MUMC+ ODIN protocol nr. 004952
- • Patients with impaired renal function (GFR \<30)
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, Limburg, Netherlands
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials